[8-K] Microbot Medical, Inc. Reports Material Event

Rhea-AI Filing Summary

Seaport Entertainment Group Inc. (NYSE American: SEG) has filed Form 25 to voluntarily remove its common stock (par value $0.01) from listing on the NYSE American and deregister it under Section 12(b) of the Securities Exchange Act of 1934. The filing relies on 17 CFR 240.12d2-2(c), indicating the issuer—not the exchange—initiated the delisting and deregistration. The document, signed by EVP & General Counsel Lucy Fato on July 8, 2025, certifies that SEG meets all Form 25 requirements.

• No financial or operational metrics are included.
• The filing covers only the company’s common stock; no other classes are mentioned.
• No explanation is provided for the voluntary withdrawal.

Positive

• None.

Negative

• Voluntary delisting from NYSE American eliminates SEG’s exchange listing, potentially reducing liquidity and visibility for shareholders.
• No stated rationale or future listing plans, leaving investors with limited information on strategic intentions.

Insights

Securities Analyst

TL;DR: SEG is voluntarily delisting from NYSE American; removal reduces public-market presence and signals potential strategic change.

The Form 25 confirms Seaport Entertainment Group Inc. will cease trading on NYSE American once the SEC’s 10-day period lapses. Because the action is voluntary under Rule 12d2-2(c), management—and not the exchange—drove the decision. While delisting can cut listing fees, it also lowers trading liquidity, analyst coverage, and transparency, typically viewed negatively by public-market investors. Absent context on motives, investors face uncertainty over future share accessibility or potential going-private actions. The absence of financial metrics or alternative listing plans means market participants have limited data to gauge impact.

false 0000883975 0000883975 2025-07-08 2025-07-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 8, 2025

MICROBOT MEDICAL INC.

(Exact name of registrant as specified in its charter)

Delaware		000-19871		94-3078125
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

175 Derby St., Bld. 27

Hingham, MA 02043

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		MBOT		NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On July 8, 2025, Microbot Medical Inc. issued a press release announcing that it is participating in the inaugural Endovascular Robotics session at the Society of Robotic Surgery (SRS) annual meeting, being held from July 16-20, in Strasbourg, France.

The press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

Exhibit		Description
99.1		Press release
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	MICROBOT MEDICAL INC.
	By:	/s/ Harel Gadot
	Name:	Harel Gadot
	Title:	Chief Executive Officer, President and Chairman

Date: July 8, 2025

FAQ

Why did Seaport Entertainment Group (SEG) file Form 25?

To voluntarily remove its common stock from listing on NYSE American and deregister it under Section 12(b).

Which SEG security is affected by the delisting?

Only the company’s common stock, par value $0.01 per share, is covered in the filing.

What rule did SEG rely on for the voluntary delisting?

SEG cited 17 CFR 240.12d2-2(c), governing issuer-initiated withdrawal from listing and registration.

Who signed the Form 25 for SEG and when?

Lucy Fato, EVP, General Counsel & Corporate Secretary, signed on July 8, 2025.

Will SEG shares trade on NYSE American after the Form 25 is effective?

No. Once the SEC’s 10-day period passes, SEG shares will no longer be listed on NYSE American.